Ind-Swift Laboratories Ltd. — Capital/Financing Update 2025

Jul 2, 2025

==> picture [476 x 85] intentionally omitted <==

Ref: ISLL:CH:2025	Date: 2nd July, 2025
To	To
Department of Corporate Services,	Department of Corporate Services,
BSE Limited	National Stock Exchange of India Limited
Phiroze Jeejeebhoy Towers,	Exchange Plaza, 5th Floor
25th Floor, Dalal Street,	Plot No. C/2, G-Block,
Mumbai 400 001	Bandra Kurla Complex, Bandra (E),
	Mumbai 400 051

BSE Scrip Code: 532305 NSE Symbol: INDSWFTLAB

SUBJECT: OUTCOME OF THE MEETING OF THE PREFERENTIAL ISSUE COMMITTEE OF THE BOARD OF DIRECTORS OF IND-SWIFT LABORATORIES LIMITED

Ref: Intimation of allotment of Equity Shares upon conversion of Warrants on preferential basis under the provisions of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("SEBI ICDR Regulations").

Dear Sir/Ma’am,

With reference to the captioned subject and in accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform your good office that the Preferential Issue Committee of the Board of Directors of Ind-Swift Laboratories Limited (“ the Company ”) at their meeting held today i.e., Wednesday, July 02, 2025, has, inter alia, considered and approved the allotment of 65,82,876 Equity Shares of face value of ₹ 10/- each pursuant to the conversion of 65,82,876 Fully Convertible Warrants (“ Warrants ”), allotted on August 30, 2024, at an issue price of ₹ 121/- each to the following allottees belonging to Promoter & Promoter Group and Non Promoter Category by way of preferential allotment on a private placement basis:

==> picture [438 x 100] intentionally omitted <==

----- Start of picture text -----

S. No. Name of the Allottees Category No. of equity shares allotted
pursuant to the conversion of
warrants
1. Essix Biosciences Limited Promoter 11,00,000
2. HCP Investments Non-Promoter 30,14,876
3. Zeal Global Opportunities Fund Non-Promoter 24,68,000
Total 65,82,876
----- End of picture text -----

Consequent to the said allotment, the Paid-up Equity Share Capital of the Company stands increased to ₹67,20,17,360/- (Rupees Sixty-Seven Crore Twenty Lakh Seventeen Thousand Three Hundred and Sixty Only) divided into 6,72,01,736 (Six Crore Seventy-Two Lakh One Thousand Seven Hundred and ThirtySix) Equity Shares of face value of ₹10/- each.

Details as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, with respect to the Preferential Allotment is enclosed as Annexure A .

Pardeep Digitally signed by Pardeep Verma Date: 2025.07.02 Verma 16:49:45 +05'30'

==> picture [476 x 85] intentionally omitted <==

The meeting of the Preferential Issue Committee of the Board of Directors was commenced at 04:00 P.M. and concluded at 04:30 P.M.

This is for your information and records.

Thanking you, Yours faithfully, For & on behalf of IND-SWIFT LABORATORIES LTD.

Pardeep Digitally signed by Pardeep Verma Verma Date: 2025.07.02 16:50:57 +05'30' PARDEEP VERMA VP-CORPORATE AFFAIRS & COMPANY SECRETARY

Annexure A

==> picture [476 x 85] intentionally omitted <==

Details on Preferential Allotment in terms of SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024:

==> picture [434 x 334] intentionally omitted <==

----- Start of picture text -----

S. No. Particulars Disclosures
1. Type of securities proposed to be Equity shares with face value of ₹10/- each
issued pursuant to the conversion of warrants.
2. Type of issuance Preferential allotment under Chapter V of the SEBI
(Issue of Capital and Disclosure Requirements)
Regulations, 2018 and other applicable law.
3. Total number of securities proposed Allotment of 65,82,876 equity shares of face value
to be issued or total amount for which ₹10/- each, pursuant to conversion of 65,82,876
the securities will be issued Fully Convertible Warrants (“Warrants”) , against
the receipt of the balance subscription amount
aggregating to ₹ 59,73,95,997/-
4. Name and number of the Investor(s) 1. Essix Biosciences Limited
2. HCP Investments
3. Zeal Global Opportunities Fund
5. Post allotment of securities- outcome Pursuant to the aforesaid allotment, the issued,
of the subscription subscribed and paid-up share capital of the
Company stands increased in the manner as set out
in the letter above.
6. Issue price / allotted price (in case of Rs. 121/- (Rupees One Hundred Twenty-One
convertibles) Only) per Equity Share.
7. In case of convertibles - The allottees mentioned above have exercised their
intimation on conversion of securities rights and converted their 65,82,876 Warrants
or on lapse of the tenure of the
instrument
----- End of picture text -----

Digitally signed Pardeep by Pardeep Verma Verma Date: 2025.07.02 16:52:05 +05'30'